Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01258205 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT01258205 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 48 participants.
The verdict
NCT01258205, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of AMG 139 following multiple intravenous (IV) or subcutaneous (SC) dose administration in healthy subjects and in subjects with mild to severe Crohn's disease (CD).
Interventions
- DRUG AMG 139
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2011-02-28 |
| Est. Completion | 2015-02-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01258205
The ClinicalTrials.gov registry entry for NCT01258205 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG 139 is the first listed.
NCT01258205 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01258205 about?
NCT01258205 is a clinical study titled "Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects". The purpose of this study is to assess the safety and tolerability of AMG 139 following multiple intravenous (IV) or subcutaneous (SC) dose administration in healthy subjects and in subjects with mild to severe Crohn's disease (CD).
What is the current status of trial NCT01258205?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2011-02-28. Estimated completion is 2015-02-18.
What interventions are being tested in trial NCT01258205?
The interventions under investigation include: AMG 139 (DRUG).
Who is sponsoring clinical trial NCT01258205?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.